| 30 Dec 2013 06:38 | Updates |
DSP Merrill Lynch Limited has submitted to the Exchange a copy of Exit offer Public Announcement made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer"). |
| 20 Dec 2013 14:02 | Delisting |
Fresenius Kabi Oncology Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting. |
| 20 Dec 2013 13:58 | Suspension and Delisting of Trading in Equity Shares |
Members of the Exchange are hereby informed that the trading in the equity shares of Fresenius Kabi Oncology Limited shall be suspended w.e.f. January 03, 2014 (i.e. w.e.f. closing hours of trading on January 02, 2014 ) on account of voluntary delisting pursuant to the SEBI (Delisting of Equity Shares) Regulations, 2009. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. January 10, 2014. Further, It may be noted that SEBI has informed the Exchange vide its letter dated December 20, 2013 that they have filed an appeal in this matter in the Hon ble Supreme Court and the outcome of the same is awaited. |
| 12 Dec 2013 03:10 | Resignation of Director |
Fresenius Kabi Oncology Limited has informed the Exchange that Dr. Patricia Grigoleit , Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013. |
| 31 Oct 2013 07:22 | Post Offer Public Announcement |
DSP Merrill Lynch Limited has submitted to the Exchange a copy Post offer Public Announcement ("Post Offer PA") is being issued by Fresenius Kabi (Singapore) Pte Ltd ("Acquirer") to the Public Shareholders of the Fresenius Kabi Oncology Limited ("Company"). This Post Offer PA is in continuation of and should be read in conjunction with, (i) the public announcement published on September 16, 2013 ( PA ) in respect of the proposed acquisition by the Acquirer and consequent delisting of the fully paid-up equity shares of the Company with a face value of Re. 1 each ("Shares") from the BSE Limited ( BSE ) and the National Stock Exchange of India Limited ( NSE ) in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 ( Delisting Regulations ), and (ii) the letter of offer issued in respect thereof inviting Bids from all Public Shareholders of the Company ( Letter of Offer ), as amended by the first corrigendum to the PA and the Letter of Offer published on October 13, 2013, the second corrigendum to the PA and the Letter of Offer published on October 19, 2013 and the supplement to the second corrigendum (to the PA and the Letter of Offer) published on October 22, 2013. This Post Offer PA is being issued in accordance with Regulation 18 of the Delisting Regulations. |
| 24 Oct 2013 09:33 | Financial Result Updates |
Fresenius Kabi Oncology Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013. |
| 22 Oct 2013 06:50 | Corrigendum |
DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Supplement to the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer"). |
| 21 Oct 2013 14:38 | Updates |
Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier letter dated October 18, 2013, informing about the Securities Appellate Tribunal's (SAT) order dated October 18, 2013, granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer, Fresenius Kabi Oncology Ltd has now informed that the Company has on October 21, 2013 has received the copy of aforementioned SAT order dated October 18, 2013. |
| 21 Oct 2013 05:54 | Corrigendum |
DSP Merrill Lynch Limited has informed the Exchange regarding the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer"). |
| 21 Oct 2013 03:18 | Updates |
Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 14, 2013. The Company has now informed the Exchange that the Company had filed a Miscellaneous Application No. 113 of 2013 in Appeal No. 133 of 2013 before the Hon'ble Securities Appellate Tribunal (SAT) seeking an extension of time to complete the Delisting Offer. The Hon'ble SAT disposed off the SAT Application on October 18, 2013. An order was passed in the open court granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer. |
